Ignite Creation Date:
2024-05-06 @ 3:25 AM
Last Modification Date:
2024-10-26 @ 11:33 AM
Study NCT ID:
NCT02281149
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-06-04
First Post:
2014-10-28
Brief Title:
Adjuvant Radiotherapy in Breast With Intensity Modulated by Tomotherapy
Sponsor:
Centre Oscar Lambret
Organization:
Centre Oscar Lambret
Study Overview
Official Title:
Adjuvant Radiotherapy in Breast With Intensity Modulated by Tomotherapy Evaluation of the Toxicity and Quality of Life
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TOMOBREAST
Brief Summary:
Adjuvant radiotherapy after lumpectomy allows a local long-term control of the order 85 to 95 with a survival rate equivalent to that of the totally mastectomy The diminution of the local recurrence rate after irradiation post- lumpectomy is also associated to a best global survival than only the surgery The adjuvant radiotherapy after partially or totally mastectomy for the progressive tumors is a therapeutic standard Early Breast Cancer Trialists Collaborative Group 2011 The aim of our trial of routine care is to record our practices under this breast adjuvant radiotherapy
Detailed Description:
Patients responding criteria for selection and not objecting to participate in this trial will address the quality of life questionnaires at baseline and during their standard follow-up 1 6 12 and 24 months after the end of radiotherapy The data of toxicity and disease-free survival will be collected from data on medical record of the patient
The therapeutic support and monitoring are standard
The therapeutic support and monitoring are standard
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None